Design, Rational Repurposing, Synthesis, In Vitro Evaluation, Homology Modeling and In Silico Study of Sulfuretin Analogs as Potential Antileishmanial Hit Compounds

Direct growth inhibition of infectious organisms coupled with immunomodulation to counteract the immunosuppressive environment might be a beneficial therapeutic approach. Herein, a library of sulfuretin analogs were developed with potential capabilities to inhibit production of the immunosuppressive PGE2 and elicit direct growth inhibition against Leishmania donovani; the major causative agent of the fatal visceral leishmaniasis. Amongst explored library members bearing diverse methoxy and/or hydroxy substitution patterns at rings B and A, analog 1i retaining the C6-hydroxy moiety at ring-A, but possessing methoxy moieties in place of the polar dihydroxy moieties of sulfuretin ring-B, as well as analog 1q retaining the sulfuretin′s polar dihydroxy moieties at ring-B, but incorporating a C6-methoxy moiety instead of the C6-hydroxy moiety at ring-A, were the most promising hit compounds. Cytotoxicity evaluation suggested that analog 1i possesses a safety profile inducing the death of the parasite rather than host cells. In silico simulation provided insights into their possible binding with Leishmania donovani fumarate reductase. The current investigation presents sulfuretin analogs 1i and 1q as potential hit compounds for further development of multifunctional therapeutic agents against visceral leishmaniasis.

[1]  Ki Duk Park,et al.  Positional scanning of natural product hispidol’s ring-B: discovery of highly selective human monoamine oxidase-B inhibitor analogues downregulating neuroinflammation for management of neurodegenerative diseases , 2022, Journal of enzyme inhibition and medicinal chemistry.

[2]  Marco Biasini,et al.  ProMod3—A versatile homology modelling toolbox , 2021, PLoS Comput. Biol..

[3]  Yong Sup Lee,et al.  Pyrrolidine-based 3-deoxysphingosylphosphorylcholine analogs as possible candidates against neglected tropical diseases (NTDs): identification of hit compounds towards development of potential treatment of Leishmania donovani , 2021, Journal of enzyme inhibition and medicinal chemistry.

[4]  Jongki Hong,et al.  Design, synthesis and cytotoxicity of chimeric erlotinib-alkylphospholipid hybrids. , 2019, Bioorganic chemistry.

[5]  Ki Duk Park,et al.  First-in-class DAPK1/CSF1R dual inhibitors: Discovery of 3,5-dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidin-5-yl)benzamide as a potential anti-tauopathies agent. , 2019, European journal of medicinal chemistry.

[6]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..

[7]  H. El Hajj,et al.  Fatal Visceral Leishmaniasis Caused by Leishmania infantum, Lebanon , 2018, Emerging infectious diseases.

[8]  T. Schwede,et al.  Modeling protein quaternary structure of homo- and hetero-oligomers beyond binary interactions by homology , 2017, Scientific Reports.

[9]  D. Steverding The history of leishmaniasis , 2017, Parasites & Vectors.

[10]  Saikat Majumder,et al.  Leishmania donovani-Induced Prostaglandin E2 Generation Is Critically Dependent on Host Toll-Like Receptor 2–Cytosolic Phospholipase A2 Signaling , 2016, Infection and Immunity.

[11]  B. Shen A New Golden Age of Natural Products Drug Discovery , 2015, Cell.

[12]  A. Harvey,et al.  The re-emergence of natural products for drug discovery in the genomics era , 2015, Nature Reviews Drug Discovery.

[13]  A. Ukil,et al.  Prostaglandin E2 Negatively Regulates the Production of Inflammatory Cytokines/Chemokines and IL-17 in Visceral Leishmaniasis , 2014, The Journal of Immunology.

[14]  Om Silakari,et al.  Multifunctional compounds: smart molecules for multifactorial diseases. , 2014, European journal of medicinal chemistry.

[15]  Jong Min Kim,et al.  Synthesis of aminoalkyl-substituted aurone derivatives as acetylcholinesterase inhibitors. , 2014, Bioorganic & medicinal chemistry.

[16]  S. Sundar,et al.  Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani , 2013, Parasitology Research.

[17]  A. Detsi,et al.  Aurones: A Promising Heterocyclic Scaffold for the Development of Potent Antileishmanial Agents , 2012, International journal of medicinal chemistry.

[18]  H. Esumi,et al.  Mitochondrial fumarate reductase as a target of chemotherapy: from parasites to cancer cells. , 2012, Biochimica et biophysica acta.

[19]  Kyung-Tae Lee,et al.  Synthesis of aurones and their inhibitory effects on nitric oxide and PGE2 productions in LPS-induced RAW 264.7 cells. , 2011, Bioorganic & medicinal chemistry letters.

[20]  Suman Gupta,et al.  Visceral leishmaniasis: Experimental models for drug discovery , 2011, The Indian journal of medical research.

[21]  Phil S Baran,et al.  Aiming for the ideal synthesis. , 2010, The Journal of organic chemistry.

[22]  P. Jaisankar,et al.  Asymmetric synthesis of N-substituted N-hydroxyureas , 2008 .

[23]  M. Nielsen,et al.  Synthetic protocols and building blocks for molecular electronics , 2005 .

[24]  Ming Chen,et al.  Aurones Interfere with Leishmania major Mitochondrial Fumarate Reductase , 2002, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[25]  L. Zhai,et al.  Purification and enzymatic activity of an NADH‐fumarate reductase and other mitochondrial activities of Leishmania parasites , 2001, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[26]  Ming Chen,et al.  Inhibition of Fumarate Reductase inLeishmania major and L. donovani by Chalcones , 2001, Antimicrobial Agents and Chemotherapy.

[27]  M. Olivier,et al.  Leishmania donovani‐induced macrophages cyclooxygenase‐2 and prostaglandin E2 synthesis , 2001, Parasite immunology.

[28]  O. Kayser,et al.  In vitro leishmanicidal activity of aurones. , 1999, Planta medica.

[29]  K. Santhamma,et al.  Characterization of the respiratory chain of Leishmania donovani promastigotes. , 1995, Molecular and biochemical parasitology.